In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
Sacituzumab govitecan (Trodelvy) appears to have more severe cytopenias and diarrhea. However, Dato-DXd and trastuzumab deruxtecan (T-DXd; Enhertu) may have more instances of interstitial lung disease ...
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer. The agent improved PFS but not OS vs. investigator’s choice of chemotherapy.
The drug, known as datopotamab deruxtecan but marketed under the brand name Datroway, is intended to treat hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2 ...
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate. This approval marks a significant ...
(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...
The drug, known in development as datopotamab deruxtecan, or Dato-DXd, will be marketed under the brand name Datroway. Datroway is part of a class of therapies called antibody drug conjugates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback